ROCKET AF Yields Positive Results For Xarelto, But A Few Chinks In The Armor
Executive Summary
Bayer/J&J’s factor Xa inhibitor Xarelto (rivaroxaban) met its endpoints in the head-to-head ROCKET AF study against warfarin, but on some major bleeding outcomes measures it actually did worse than warfarin, and the effects of the widely used generic appear to have been sub-par in the 14,000-patient study.
You may also be interested in...
Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry
Published results from the Xarelto (rivaroxaban) pivotal trial in atrial fibrillation throw more light on the efficacy and safety concerns likely to be aired at a Sept. 8 FDA advisory committee review of the Bayer/Johnson & Johnson anticoagulant.
Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry
Published results from the Xarelto (rivaroxaban) pivotal trial in atrial fibrillation throw more light on the efficacy and safety concerns likely to be aired at a Sept. 8 FDA advisory committee review of the Bayer/Johnson & Johnson anticoagulant.
Bristol R&D Update: Apixaban Filing Delayed, Ipilimumab Approval Expected
Contrary to expectations, Bristol-Myers Squibb will not file early for a narrow indication of the novel anticoagulant apixaban.